Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
-0.91 (-3.41%)
After Hours: 25.81 0.00 (0.00%)
Feb 11, 4:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.07 - 26.42
52 week 20.05 - 35.79
Open 26.06
Vol / Avg. 0.00/274,377.00
Mkt cap 820.87M
P/E     -
Div/yield     -
EPS -1.14
Shares 32.54M
Beta 0.57
Inst. own 95%
May 3, 2016
Q1 2016 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2016
Q4 2015 Genomic Health Inc Earnings Call
Feb 10, 2016
Q4 2015 Genomic Health Inc Earnings Release
Jan 11, 2016
Genomic Health Inc at JPMorgan Healthcare Conference
Nov 19, 2015
Genomic Health Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -16.10% -8.92%
Operating margin -7.39% -8.57%
EBITD margin - -6.08%
Return on average assets -25.62% -13.55%
Return on average equity -33.58% -16.93%
Employees 752 -
CDP Score - -


301 Penobscot Dr
REDWOOD CITY, CA 94063-4700
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Genomic Health, Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company's Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
G Bradley Cole Chief Financial Officer, Chief Operating Officer, Secretary
Age: 59
Bio & Compensation  - Reuters
Steven Shak M.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 59
Bio & Compensation  - Reuters